Fig. 6: Gilteritinib treatment affects additional pathways and downregulates unique EC-, OC-, and GC-associated prognostic genes.
From: Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors
A The top ranked positively and negatively enriched gene sets identified using Gene Set Enrichment Analysis (GSEA) in response to gilteritinib treatment. GSEA was conducted in KYSE30, A2780, and HGC-27 cells after gilteritinib treatment using the 50 HALLMARK gene sets database in MSigDB. GSEA plots showing strong positive enrichment of the cholesterol_homeostasis pathway (B), negative enrichment of the E2F and MYC targets v1 (C) in KYSE30, A2780, and HGC-27 cells in response to gilteritinib. NES Normalized enrichment score, FDR False discovery rate. D Kaplan–Meier estimate of overall survival based on DEG expression (TCGA EC, OC, and GC cohort). Relative high expression of CENPE, MCM4, GSPT1, MMS22L, DDX21, VDAC1, FDX1, OPA1, PDHX, ELOA, BCL3, and RACGP1 genes was associated with poor overall survival in the EC, OC, and GC cohort. Log rank (Mantel-Cox) test was used for significance; p < 0.05 was considered significant.
